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TLR-4 deficiency protects against focal cerebral ischemia and
axotomy-induced neurodegeneration
Abstract
The pattern recognition receptor toll-like receptor (TLR)-4 mediates innate danger signaling in the brain,
being activated in response to lipopolysaccharide. Until now, its role in the degenerating brain remained
unknown. We here examined effects of a loss-of-function mutation of TLR-4 in mice submitted to
transient focal cerebral ischemia and retinal ganglion cell (RGC) axotomy, which are highly
reproducible and clinically relevant in vivo models of acute and subacute neuronal degeneration. We
show that TLR-4 deficiency protects mice against ischemia and axotomy-induced RGC degeneration.
Decreased phosphorylation levels of the mitogen-activated kinases ERK-1/-2, JNK-1/-2 and p38
together with reduced inducible NO synthase levels in injured neurons of TLR-4 mutant mice suggests
that TLR-4 deficiency downscales parenchymal stress responses, thereby enhancing neuronal survival.
At the same time, densities of MPO+ neutrophils and Iba1+ microglial cells were increased in the brains
of TLR-4 mutant animals, pointing towards a futile inflammatory response aiming to compensate lost
functions. Our data indicate that innate immunity may represent an attractive target for neuroprotective
treatments in stroke and neurodegeneration.
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Abstract  
Background and Purpose - The pattern recognition receptor toll-like receptor (TLR)-
4 mediates innate danger signaling in the brain, being activated in response to 
lipopolysaccharide. Until now, its role in the degenerating brain remained unknown. 
Methods - We here examined effects of a loss-of-function mutation of TLR-4 in mice 
submitted to transient focal cerebral ischemia and retinal ganglion cell (RGC) 
axotomy, which are highly reproducible and clinically relevant in vivo models of acute 
and subacute neuronal degeneration.  
Results - We show that TLR-4 deficiency protects mice against ischemia and 
axotomy-induced RGC degeneration. Decreased phosphorylation levels of the 
mitogen-activated kinases ERK-1/-2, JNK-1/-2 and p38 together with reduced 
inducible NO synthase levels in injured neurons of TLR-4 mutant mice suggest that 
TLR-4 deficiency downscales parenchymal stress responses, thereby enhancing 
neuronal survival.  
Conclusions - Our data indicate that innate immunity may represent an attractive 
target for neuroprotective treatments in stroke and neurodegeneration. 
Key Words: innate immune system, danger signaling, ischemic stroke, 
neurodegeneration. 
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The injured brain is particularly vulnerable to environmental stimuli. As such, brain 
cells may remain viable under conditions of ischemia or trauma, but activate death 
programs when exposed to additional stressors, such as organic toxins1 or pro-
inflammatory signals.2 To protect itself from injury, the brain has developed its own 
endogenous strategies.  
Along the blood-brain barrier (BBB), so-called ATP-binding cassette (ABC) 
transporters are expressed on capillary cells that actively eliminate natural 
compounds from the brain.3-5 ABC transporters are specifically regulated in response 
to ischemia6 and other kinds of brain injury,1,4 thus providing a highly efficacious 
barrier for environmental toxins. 
In the surrounding of brain capillaries, perivascular dendritic and macrophages 
are located, which together with brain-resident microglia represent an innate 
surveillance system in the immune-privileged brain.7 This task is achieved by so-
called pathogen-recognition receptors (PRR), which recognize conserved microbial 
motifs.8-10  
Among the pathogen-associated molecular patterns (PAMP) recognized by 
brain-resident microglia, lipopolysaccharides (LPS), i.e., cell wall constituents of 
gram-negative bacteria, play a very important role, being detected by a PRR termed 
toll-like receptor (TLR)-4.11 TLR-4 is a leucine-rich transmembrane protein, named 
after the toll protein in drosophila, where this receptor family was first described.12  
Once stimulated by LPS, TLR-4 activates a variety of signal pathways in the 
cytosol of immune cells. Via its cytosolic Toll/ interleukin-1 (IL-1) receptor homology 
domain (TIR), TLR-4 stimulates mitogen-activated protein (MAP) and stress kinases, 
such as extracellular-regulated kinase (ERK)-1/-2, Jun kinase (JNK)-1/-2 and p38, 
which in turn activate transcription regulators of inflammation in the nucleus.13 
Activation of TLR-4 enables microglial cells to remove LPS from the brain tissue.10 
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In view of the complex downstream responses activated by LPS we wondered 
how TLR-4 deactivation influences cell injury under conditions in which neurons are 
lost. We therefore investigated the effect of the loss-of-function mutation of TLR-4 in 
the C3H/HeJ mouse line on injury development and cell signaling in two models of 
brain disease, i.e., i.) after focal cerebral ischemia, induced by intraluminal middle 
cerebral artery (MCA) occlusion,7,14 and ii.) after retinal ganglion cell (RGC) axotomy, 
induced by optic nerve (ON) transsection.15,16  
  
Materials and methods 
Animals 
All experimental procedures were carried out with government approval according to 
NIH guidelines for the care and use of laboratory animals. Adult male C3H/HeJ mice, 
which carry a point mutation in the cytosolic domain of the TLR-4 protein resulting in 
the exchange of amino acid 712 from proline to histidine that abrogate receptor 
functionality,17 and TLR-4-wildype (wt) C3H/HeN controls were purchased from the 
Jackson Laboratory. Animals were subjected to transient focal cerebral ischemia, 
induced by 90 min or 30 min of MCA occlusion, or underwent RGC axotomy by ON 
transsection (n = 6 animals / group). 
 
Experimental procedures: Transient focal brain ischemia 
Animals (9-11 weeks) were anesthetized with 1% halothane (30% O2, remainder 
N2O). Rectal temperature was maintained between 36.5 and 37.0°C using a 
feedback-controlled heating system. During the experiments, blood flow was 
measured by laser Doppler flow (LDF) measurements using a flexible 0.5 mm fiber 
optic probe (Perimed, Stockholm, Sweden), which was attached to the intact skull 
overlying the middle cerebral artery (MCA) territory (2 mm posterior / 6 mm lateral 
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from bregma). LDF changes were monitored up to 30 min after the onset of 
reperfusion. Focal ischemia was induced using an intraluminal filament 
technique.14,18 A midline neck incision was made, and the left common and external 
carotid arteries were isolated and ligated. A microvascular clip (FE691, Aesculap, 
Tuttlingen, Germany) was temporarily placed on the internal carotid artery. A 8-0 
nylon monofilament (Ethilon; Ethicon, Norderstedt, Germany) coated with silicon 
resin (Xantopren, Bayer Dental, Osaka, Japan; diameter of the coated thread: 190-
200 µm) was introduced through a small incision into the common carotid artery and 
advanced 9 mm distal to the carotid bifurcation for MCA occlusion. Either 30 min or 
90 min after MCA occlusion, reperfusion was initiated by withdrawal of the 
monofilament. Anesthesia was discontinued and animals were placed back into their 
cages. Twenty-four hours (90 min MCA occlusion) or 72 hours (30 min) later, animals 
were deeply re-anesthetized and decapitated. Brains were removed and cut on a 
cryostat in 18 μm coronal sections. 
 
Experimental procedures: Optic nerve (ON) transsection 
For retrograde labeling of RGC, animals (12-14 weeks) were i.p. anesthetized with 
7% chloral hydrate. The superior colliculi were exposed via a bur hole that was drilled 
into the pericranium 0.7 mm lateral to the sagittal suture and 3 mm posterior to the 
bregma. A Hamilton syringe was inserted 2.0 mm beneath the brain surface, and 0.7 
µl of fluorogold (infusion rate 0.7 µl/ min) was injected stereotactically into both 
superior colliculi.15,16 After infusion, the injection needle remained inside the tissue for 
2 min to prevent fluorogold diffusion along the needle track, before the syringe was 
withdrawn.  
Four days after labeling, mice were re-anesthetized with 7% chloral hydrate. 
After skin incision close to the superior orbital rim, the right orbita was opened, 
Neuroprotection by TLR-4 deficiency /  9
 
leaving the supraorbital vein intact, and the lacrimal gland was resected subtotally. 
After spreading the superior extraocular muscles, the right ON was transected under 
microscopical control approximately 0.5 mm distant to the posterior pole of the eye, 
taking care not to damage the retinal blood vessels. The wounds were sutured and 
the retinal blood supply was verified by fundoscopy.16 
Fourteen days after ON transsection, mice were killed with an overdose of 
chloral hydrate and both eyes were removed. The retinas were dissected, flat-
mounted on glass slides, and fixed in 4% paraformaldehyde (PFA) in 0.1 M 
phosphate-buffered saline (PBS) for 30 min.  
 
Analysis of histological injury 
Infarct volumetry and brain edema. Brain sections were fixed for 10 min with 4% PFA 
in 0.1 M PBS and subsequently stained with cresyl violet. For infarct volumetry and 
assessment of brain edema, a total of four sections from equidistant brain levels, 2 
mm apart, were analyzed in animals submitted to 90 min MCA occlusion (sections 
selected starting from the rostral pole of the striatum: bregma +2.0 mm, subsequent 
sections taken from bregma 0.0, -2.0 and -4.0 mm). On these sections, brain infarcts 
were outlined by delineating lesioned and non-lesioned tissue in both hemispheres, 
thereby determining edema-corrected infarct areas and brain edema, subsequently 
calculating infarct volumes. 
Analysis of surviving neurons. In animals submitted to 30 min MCA occlusion cresyl 
violet-stained sections from the bregma level were microscopically evaluated by 
counting the density of surviving medium- to large-sized neurons in the striatum in a 
total of nine random regions of interest (ROI), 1 mm apart, each measuring 62’500 
µm2.18 Stereological analysis was done by one of the investigators blinded for the 
experimental condition (Ü.K.). Mean values were calculated for all areas both 
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ipsilateral and contralateral to the stroke. Thereby, the percentage of surviving 
neurons was determined. 
Analysis of DNA fragmented cells. From animals subjected to 30 minutes MCA 
occlusion, sections from the level of the mid-striatum (bregma 0.0 mm) were stained 
by terminal transferase biotinylated-dUTP nick end labeling (TUNEL) using a 
commercially available kit (Roche, Basle, Switzerland).14 In these sections, DNA 
fragmented cells were counted in blinded manner (again done by Ü.K.) in the same 
nine random ROI in the striatum (each 62’500 µm2) as above.  
Evaluation of RGC survival by stereology of surviving RGCs. Surviving RGCs were 
evaluated by fluorescence microscopy using retinal whole-mounts using a rhodamine 
filter (546/590 nm). RGC densities were determined by counting tracer-labeled RGCs 
in 12 random ROI (three areas per retinal quadrant at different eccentricities of 1/6, 
3/6 and 5/6 of the retinal radius, respectively; measuring 62’500 μm2 each).16 Mean 
values were calculated for all eccentricities as well as over the whole retina. 
 
Activation of MAP kinases ERK-1/-2, JNK-1/-2 and p38 
Tissue samples harvested from the ischemic MCA territory of C3H/HeJ and 
C3H/HeN mice subjected to 30 min MCA occlusion (72 h reperfusion) were 
complemented with lysis buffer, homogenized and centrifuged. Supernatants were 
used for sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Prior to processing, samples from animals belonging to the same experimental group 
(n = 6 animals/ group) were pooled. After SDS-PAGE, proteins were transferred onto 
PVDF membranes. Membranes were dried, incubated in blocking solution and 
immersed with polyclonal rabbit anti-total (= detecting both the phosphorylated and 
unphosphorylated forms) ERK-1/-2 (9102; Cell Signaling, Allschwil, Switzerland), 
mouse anti-phospho-ERK-1/-2 (M8159; Sigma, Deisenhofen, Germany), rabbit anti-
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total JNK-1/-2 (JNK-2, sc-572; Santa Cruz), rabbit anti-phospho-JNK-1/-2 (9251; Cell 
Signaling), rabbit anti-total p38 (9212, Cell Signaling) or rabbit anti-phospho-p38 
(9211, Cell Signaling)  antibody, each diluted 1:500 in 0.1% Tween 20/ 0.1 M Tris 
buffered saline (TBS).16 Membranes were rinsed, incubated in peroxidase-coupled 
secondary antibodies, diluted 1:2000 in 0.1% Tween 20/ 0.1 M TBS, washed, 
immersed in enhanced chemoluminescence (ECL) solution and exposed to ECL-
Hyperfilm (Amersham, Braunschweig, Germany). Protein loading was controlled with 
a monoclonal mouse antibody against anti-β-actin (A5316; Sigma). Blots were 
performed at least three times. Protein levels were analyzed densitometrically, 
corrected with values determined on anti-β-actin blots and expressed as relative 
values compared with wt mice. 
 
Expression of activated caspase-3 and inducible NO synthase (iNOS) 
Brain sections were fixed in 4% PFA in 0.1 M PBS, washed and immersed for 1 h in 
0.1 M PBS containing 0.3% Triton X-100 (PBS-T)/ 10% normal goat serum. Sections 
were incubated overnight at 4°C with polyclonal rabbit anti-activated caspase-3 (CM-
1; BD Biosciences, Basle, Switzerland) or anti-iNOS (NOS-2, sc-650; Santa Cruz, 
Nunningen, Switzerland) antibody, diluted 1:100 in PBS-T. Counterstainings were 
performed with a monoclonal mouse antibody against the neuronal nuclear protein 
NeuN (MAB377; Chemicon, Lucerne, Switzerland; 1:500). After staining with Cy3-
labeled (iNOS, caspase-3) and FITC-labeled (NeuN) secondary antibody, sections 
were incubated with 4',6-diaminido-2-phenylidole (DAPI) and coverslipped. Sections 
were microscopically analyzed by counting activated caspase-3(+) and iNOS(+) cells 
in six random ROI each in the ischemic parietal cortex and ischemic striatum (62’500 
µm2), for which mean values were calculated.14  
 
Neuroprotection by TLR-4 deficiency /  12
 
Analysis of polymorphonuclear neutrophil (PMN) recruitment 
For assessment of PMN recruitment, myeloperoxidase (MPO) stainings were 
prepared with Histostain®-Plus kits (Zymed Laboratories, San Francisco, CA). Brain 
sections were fixed in 4% PFA in 0.1 M PBS, washed in water and boiled in 0.01 M 
citrate buffer for 15 min for epitope retrieval. Sections were incubated in 0.3% H2O2 
peroxidase quenching solution for 10 min, followed by serum blocking solution for 30 
min. Sections were then incubated with rabbit anti-MPO antibody (Zymed 
Laboratories, San Francisco, CA), diluted 1:100 in 5% normal goat serum in 0.3% 
Triton X-100/ 0.1 M PBS for 60 min, followed by incubation in a biotinylated 
secondary antibody for 10 min. Following signal detection with diaminobenzidine, 
sections were counterstained with hematoxyline. MPO(+) PMN were microscopically 
identified based on morphological criteria, evaluating only cells with multilobed nuclei. 
PMNs were further distinguished from eosinophilic and basophilic cells based on 
hematoxyline staining properties. Sections were analyzed by counting MPO(+) cells 
in six random ROI each in the ischemic parietal cortex and ischemic striatum 
(measuring 62’500 µm2), for which mean values were calculated. 
 
Statistics 
All values are given as mean ± SD. Differences between groups were compared by 
independent two-tailed t-tests. P values < 0.05 were considered to indicate statistical 
significance. 
 
Results 
TLR-4 deficiency protects against focal cerebral ischemia 
Laser Doppler flowmetry. To evaluate effects of TLR-4 deficiency on cerebral blood 
flow during and after MCA occlusion, LDF recordings were analyzed. In our studies, 
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MCA occlusion resulted in a decrease of LDF values to ∼15% of pre-ischemic levels 
(Fig. 1A, Fig. 2A). After reperfusion, LDF values normalized rapidly in animals 
subjected to 90 min MCA occlusion (Fig. 1A), but slightly increased above pre-
ischemic values in animals submitted to 30 min ischemia (Fig. 2A). No differences 
were detected between wt and TLR-4 mutant (mt) mice. 
Infarct volume and brain edema. As in previous studies,7,14,18 90 min MCA occlusion 
resulted in focal infarcts of the cerebral cortex and underlying striatum in wt mice 
(Fig. 1B) that was reproducibly associated with brain edema (Fig. 1C). TLR-4 
deficiency decreased infarct volume (Fig. 1B), without influencing brain swelling (Fig. 
1C). 
Disseminate neuronal injury and caspase-3 activation. As in earlier reports,7,18 30 min 
MCA occlusion induced disseminate neuronal injury in the striatum (Figs. 2B, C) that 
was accompanied by activation of caspase-3 (Fig. 2D). TLR-4 deficiency increased  
the percentage of surviving striatal neurons (Fig. 2B), reduced the density of DNA-
fragmented, i.e., injured cells (Fig. 2C), and diminished caspase-3 activity (Fig. 2D). 
 
TLR-4 mutation promotes the survival of axotomized RGCs 
In non-lesioned retinae of wt and TLR-4 deficient mice, RGC densities of 3321.1 ± 
508.8/ mm2 and 4115.7 ± 263.2/ mm2 were determined, which is in line with earlier 
results from our group.15,16 Upon ON transsection, reproducible RGC degeneration 
was noticed in retinae of wt mice, ~75% of RGCs undergoing delayed degeneration 
within 14 days (Figs. 3A, B). RGC damage was attenuated by TLR-4 deficiency (Figs. 
3A, B). 
 
TLR-4 deficiency reduces phosphorylation levels of ERK-1/-2, JNK-1/-2 and p38 
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To elucidate mechanisms underlying the neuroprotective effect of TLR-4 deficiency, 
Western blots were prepared using protein extracts obtained from brains subjected to 
focal cerebral ischemia. Western blots obtained with antibodies recognizing both 
unphosphorylated and phosphorylated MAP kinases revealed no differences in the 
overall expression of ERK-1/-2, JNK-1/-2 and p38 between wt and TLR-4 mt mice 
(Fig. 4). Phosphorylation levels of ERK-1/-2, JNK-1/-2 and p38, on the other hand, 
were markedly reduced by TLR-4 deficiency (Fig. 4). 
 
TLR-4 deactivation downregulates neuronal iNOS expression 
To evaluate how TLR-4 deficiency influences the expression of the pro-inflammatory 
protein iNOS, immunohistochemistries were evaluated. In animals submitted to 90 
min, but not 30 min MCA occlusion, robust iNOS expression was noted in the 
ischemic brain parenchyma of wt mice that in the vast majority of cells (>80%) 
collocalized with the neuronal nuclear protein NeuN (Fig. 5A). TLR-4 deficiency 
downregulated neuronal iNOS levels in the ischemic brain tissue (Fig. 5A).  
 
TLR-4 deficiency associated with compensatory PMN recruitment 
To find out how TLR-4 deficiency influences the brain accumulation of blood-derived 
PMN, which similar to brain-derived microglial cells and macrophages express TLR-4 
on their cell surface,9 immunohistochemistries for MPO were prepared. Significant 
PMN recruitment was noted in ischemic brain areas in animals subjected to 90 min, 
but not 30 min MCA occlusion in wt mice (Fig. 5B). TLR-4 deficiency increased the 
PMN density in the ischemic tissue (Fig. 5B), most likely as compensatory 
mechanism counteracting the TLR-4 defect. 
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Discussion 
We show that TLR-4 deficiency protects against rapidly developing ischemic and 
slowly progressive degenerative neuronal injury in vivo by mechanisms involving 
deactivation of ERK-1/-2, JNK-1/-2 and p38, downregulation of iNOS and inhibition of 
the executioner caspase-3. Our data were obtained using i.) the intraluminal MCA 
occlusion model, a highly reproducible and clinically relevant model of ischemic 
stroke, in which we evaluated two different durations of ischemia that result in 
reproducible brain infarcts (90 min MCA occlusion)7,14,19 or disseminate neuronal 
injury (30 min ischemia),7,18,20 and ii.) a model of RGC axotomy, in which the ON is 
cut close to the posterior eye pole.16,21,22 ON transsection leads to the degeneration 
of ~80% of RGCs within 14 days post-injury,16,21,22 thus mimicking more delayed 
neurodegenerative processes. 
In our studies, we made use of the C3H/HeJ mouse line, which expresses a 
non-functional TLR-4 protein due to a point mutation in the receptor’s cytosolic 
domain.17 While this paper was in the final stage of preparation, a manuscript from 
another group showed that tlr-4 deletion in C57bl/10ScNJ mice similar to loss-of-
function mutant TLR-4 in C3H/HeJ animals reduces cortical injury following 
permanent MCA electrocoagulation.23 That tlr-4 knockout also promotes neuronal 
survival supports our present findings, providing additional evidence for TLR-4’s 
harmful effects.  
That TLR-4 deficiency protects against neuronal injury exemplifies the 
relationship between immune responses and neuronal degeneration, pointing out 
that signal responses triggered by PRR might set the pace for cell death programs.24 
Our data suggest that TLR-4 might represent a promising target for neuroprotective 
therapies. TLR-4 is constitutively expressed in the CNS on microglia and 
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macrophages,9 being involved in danger signaling to LPS, an outer cell wall 
constituent of gram-negative bacteria.11 
By demonstrating that TLR-4 reduces ERK-1/-2, JNK-1/-2 and p38 
phosphorylation, we provide insights into the mechanisms of neuroprotection induced 
by TLR-4 deficiency. In cultured macrophages, the LPS-induced release of tumor 
necrosis factor (TNF)-α was previously shown to be mediated by MAP kinases.13 
Deactivation of TLR-4 using a monoclonal antibody abolished LPS-induced ERK-1/-2 
phosphorylation, while pharmacological  ERK-1/-2 and p38 blockade prevented LPS-
induced TNF-α secretion.13 By revealing that ERK-1/-2, JNK-1/-2 and p38, which are 
activated upon ischemia in wt mice,25 are dephosphorylated when TLR-4 is 
deactivated, we for the first time show that MAP kinases are involved in TLR-4 
signaling in vivo. 
Among the effectors contributing to immune-mediated injury in stroke and 
neurodegenerative diseases, iNOS is a well-established player (reviewed in refs. 26, 
27). Being induced in ischemic neurons14 and axotomized RGCs,22 iNOS contributes 
to oxidative stress via formation of nitrite and nitrate.26,27 By showing that TLR-4 
deficiency downregulates iNOS in NeuN(+) ischemic neurons, we provide a link 
between immune surveillance, TLR-4-mediated cell signaling and neuronal injury 
pathways. Thus, a crosstalk exists between TLR-4(+) microglia and macrophages 
with brain neurons, which may explain TLR-4’s neurodegeneration-promoting effects. 
In contrast to neuronal iNOS that was reduced by TLR-4 deficiency, the 
recruitment of blood-derived PMN to the ischemic tissue was increased in our 
C3H/HeJ mouse line. PMN leucocytes similar to brain-resident microglia and 
macrophages express TLR-4 on their cell surface.9 That PMN accumulation was 
increased in the brains of ischemic TLR-4 mt animals might represent a 
compensatory mechanism, aiming to counterbalance consequences of the gene 
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defect. Apparently, the increased PMN recruitment did not exert any injurious effect, 
pointing out that PMN invasion is not necessarily detrimental to the brain. 
The enhanced neuronal survival in TLR-4 deficient mice raises the question 
whether deactivation strategies of innate immune receptors may be used for clinical 
purposes in the future. Our here-presented data support this fascinating idea. Yet, 
when evaluating strategies of PRR blockade, long-term effects of receptor 
deactivation for immune function should carefully be considered. Rodent studies 
have shown that stroke represents a particularly vulnerable immunodepressant state 
in which bacterial infection may occur more easily than normal.28 Thus, care must be 
taken that survival-promoting effects are not achieved at the expense of infectious 
states. Further studies should further elucidate the therapeutic potential of strategies 
modulating PRR signaling in ischemic stroke and neurodegenerative diseases. Such 
studies may help to clarify whether innate immunity is indeed a promising target for 
neuroprotection therapies. 
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Legends to Figures: 
Figure 1. TLR-4 deficiency reduces ischemic infarct volume after transient focal 
cerebral ischemia. Laser Doppler flow (LDF) during and after ischemia (A), infarct 
volume (B), and brain swelling (C) in TLR-4 wt and TLR-4 mt mice submitted to 90 
min MCA occlusion, followed by 24 hours reperfusion. Representative cresyl violet-
stained sections are also shown (B). Note that LDF (A) and brain edema (C) do not 
differ between mouse lines. Data are means ± SD (n = 6 animals/ mouse line). *p< 
0.05 (two-tailed t-tests). Bar, 2 mm. 
 
Figure 2. Loss-of-function mutant TLR-4 promotes neuronal survival, decreases DNA 
fragmentation and reduces caspase-3 activation in the mouse striatum. LDF during 
and after ischemia (A), neuronal survival assessed by cresyl violet staining (B), DNA-
fragmented cells evaluated by TUNEL (C), and activated caspase-3(+) cells (D) in 
TLR-4 wt and TLR-4 mt mice subjected to 30 min MCA occlusion, followed by 72 
hours reperfusion. Note again that LDF does not differ between mouse lines (A). 
Data are means ± SD (n = 6 animals/ mouse line). *p< 0.05 (two-tailed t-tests). 
 
Figure 3. TLR-4 deficiency protects axotomized RGCs from retrograde degeneration. 
Survival rates of fluorogold-prelabeled RGCs in TLR-4 wt and TLR-4 mt mice 
submitted to ON transsection, followed by 14 survival. Survival rates averaged over 
the whole retina (A) and also survival rates at various retinal eccentricities (B) are 
shown. Data are means ± SD (n = 6 animals/ mouse line). *p< 0.05 (two-tailed t-
tests). 
 
Figure 4. Mutant TLR-4 decreases phosphorylated, but not total ERK-1/-2, JNK-1/-2 
and p38. Western blots with protein extracts of tissue samples obtained from the 
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ischemic cortex and underlying striatum of TLR-4 wt and TLR-4 mt mice submitted to 
30 min MCA occlusion. Membranes were incubated with antibodies detecting both 
phosphorylated and non-phosphorylated (=total) protein kinases as well as antibodies 
that only recognize the phosphorylated, i.e., activated forms. Representative blots are 
also shown. Data are mean ± S.D. (n = 3 different blots/ mouse line), normalized with 
corresponding blots for β-actin. *p< 0.05 (two-tailed t-tests). 
 
Figure 5. TLR-4 deficiency downregulates inducible NO synthase (iNOS) in injured 
neurons, at the same time increasing polymorphonuclear neutrophil (PMN) 
recruitment to the stroke tissue. Density of iNOS+ neurons (A) and myeloperoxidase 
(MPO)+ neutrophils (B) in TLR-4 wt and TLR-4 mt mice submitted to 90 min MCA 
occlusion, followed by 24 hours reperfusion. Representative microphotographs 
exhibiting iNOS+/ NeuN+ neurons in the ischemic cortex are shown (A; 
counterstained with DAPI). Representative myeloperoxidase (MPO)+ PMN in the 
cortex are also depicted (B; counterstained with hematoxylin; MPO-labeled PMN: see 
flashes). Data are means ± SD (n = 6 animals/ mouse line). *p< 0.05 (two-tailed t-
tests). Bar, 50 µm. 
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